How does NPO-2270 compare to enalapril in treating heart failure?
Label:chem
Topic
Enalapril is an ACE inhibitor commonly used as a first-line treatment for heart failure. NPO-2270 is a novel cysteine protease inhibitor that has shown potential in preclinical studies to reduce myocardial infarction and adverse remodeling.
Answer
NPO-2270 is more effective than enalapril in preserving cardiac function and preventing adverse remodeling in murine models of heart failure. It reduces calpain activity and preserves the structural integrity of cardiac proteins such as junctophilin-2, leading to better cardiac function outcomes compared to enalapril.
Return to Home
Chemical List
Knowledge you may be interested in